Is there an interest in systematic serum screening for aspergillosis in COVID-19 patients in a medical ward?
Victor Gerber(Institut de Virologie), François Danion(Hôpitaux Universitaires de Strasbourg), Raoul Herbrecht(Institut de Cancérologie Strasbourg), Yves Hansmann(Hôpitaux Universitaires de Strasbourg), Louis Boehn(Hôpitaux Universitaires de Strasbourg), Marcela Sabou(Amgen (United States)), Nicolas Lefèbvre(Hôpital Civil, Strasbourg), Antoine Studer(Hôpitaux Universitaires de Strasbourg), Valérie Letscher‐Bru, Axel Ursenbach(Hôpitaux Universitaires de Strasbourg)
Cited by 0
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2016|2.8k
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
|Clinical Infectious Diseases|2008|2.7k
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k